Abstract
Systemic juvenile idiopathic arthritis (SJIA), presently included under the broad taxonomy of Still’s disease along with ‘Adult-onset Stills disease’, is a unique disease entity, characterised predominantly by features of systemic inflammation at disease onset and running a heterogenous course, evolving into a disabling chronic, destructive arthritis in a sizable proportion of patients. With a better understanding of the disease biology, there has been a paradigm shift in therapeutic strategy targeting immunological remission. With the evolution of better biomarkers (to guide diagnosis, predict complications and predict treatment responses) and robust therapeutic options and treatment targets, newer challenges such as refractory disease states and SJIA-associated lung disease have risen to the fore, making disease management all the more challenging.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
